GBR-13119: Difference between revisions

Latest revision as of 03:35, 13 February 2025

GBR-13119[edit]

GBR-13119 is a chemical compound that acts as a potent and selective dopamine reuptake inhibitor. It is part of the piperazine class of drugs and has been studied for its potential use in the treatment of various neurological and psychiatric disorders.

Pharmacology[edit]

GBR-13119 functions primarily by inhibiting the reuptake of dopamine in the brain. This action increases the concentration of dopamine in the synaptic cleft, thereby enhancing dopaminergic neurotransmission. The compound binds to the dopamine transporter (DAT) with high affinity, preventing the reabsorption of dopamine into the presynaptic neuron.

Mechanism of Action[edit]

The mechanism of action of GBR-13119 involves its interaction with the dopamine transporter (DAT). By binding to DAT, GBR-13119 blocks the reuptake of dopamine, leading to increased levels of dopamine in the synaptic cleft. This results in prolonged dopaminergic signaling, which can affect various physiological and behavioral processes.

Potential Therapeutic Uses[edit]

GBR-13119 has been investigated for its potential therapeutic applications in several conditions, including:

Research and Development[edit]

Research on GBR-13119 has primarily focused on its pharmacological properties and potential therapeutic benefits. Studies have shown that it can effectively increase dopamine levels in the brain, which may be beneficial in treating disorders characterized by dopamine dysregulation.

Safety and Side Effects[edit]

As with other dopamine reuptake inhibitors, GBR-13119 may have side effects related to its dopaminergic activity. Potential side effects include:

Related Compounds[edit]

GBR-13119 is structurally related to other piperazine derivatives, such as GBR-12909 and GBR-12935, which also act as dopamine reuptake inhibitors.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''GBR-13119''' is a [[psychoactive drug]] and [[research chemical]] of the [[diphenylmethane]] class. It acts as a potent and selective [[dopamine reuptake inhibitor]] (DRI) and is the most selective DRI known, with 1,000-fold selectivity for dopamine over [[norepinephrine]] and [[serotonin]]. GBR-13119 was developed in the 1980s by the pharmaceutical company [[G.D. Searle & Company]].
+== GBR-13119 ==
-==Pharmacology==
+[[File:GBR-13119.svg|thumb|right|Chemical structure of GBR-13119]]
-GBR-13119 is a potent inhibitor of the [[dopamine transporter]] (DAT), which is responsible for the reuptake of dopamine in the [[synapse]]. By blocking this transporter, GBR-13119 increases the amount of dopamine available in the synapse, leading to increased [[dopaminergic]] activity. This can result in effects such as increased alertness, euphoria, and increased motor activity.
-==Chemistry==
+'''GBR-13119''' is a chemical compound that acts as a potent and selective [[dopamine reuptake inhibitor]]. It is part of the [[piperazine]] class of drugs and has been studied for its potential use in the treatment of various neurological and psychiatric disorders.
-GBR-13119 is a member of the [[diphenylmethane]] class of compounds, which also includes other DRIs such as [[GBR-12909]] and [[GBR-13069]]. It is structurally related to these compounds, with the main difference being the substitution of a [[fluorine]] atom at the 4-position of one of the phenyl rings.
-==Research==
+== Pharmacology ==
-Research into GBR-13119 has primarily focused on its potential use in the study of [[dopamine]] function and related disorders, such as [[Parkinson's disease]] and [[schizophrenia]]. However, its high selectivity for the dopamine transporter over other monoamine transporters has limited its clinical utility.
+GBR-13119 functions primarily by inhibiting the reuptake of [[dopamine]] in the brain. This action increases the concentration of dopamine in the synaptic cleft, thereby enhancing dopaminergic neurotransmission. The compound binds to the dopamine transporter (DAT) with high affinity, preventing the reabsorption of dopamine into the presynaptic neuron.
+== Mechanism of Action ==
+The mechanism of action of GBR-13119 involves its interaction with the [[dopamine transporter]] (DAT). By binding to DAT, GBR-13119 blocks the reuptake of dopamine, leading to increased levels of dopamine in the [[synaptic cleft]]. This results in prolonged dopaminergic signaling, which can affect various physiological and behavioral processes.
+== Potential Therapeutic Uses ==
+GBR-13119 has been investigated for its potential therapeutic applications in several conditions, including:
+* [[Attention deficit hyperactivity disorder]] (ADHD)
+* [[Parkinson's disease]]
+* [[Depression]]
+* [[Substance use disorders]]
+== Research and Development ==
+Research on GBR-13119 has primarily focused on its pharmacological properties and potential therapeutic benefits. Studies have shown that it can effectively increase dopamine levels in the brain, which may be beneficial in treating disorders characterized by dopamine dysregulation.
+== Safety and Side Effects ==
+As with other dopamine reuptake inhibitors, GBR-13119 may have side effects related to its dopaminergic activity. Potential side effects include:
+* [[Insomnia]]
+* [[Anxiety]]
+* [[Increased heart rate]]
+* [[Hypertension]]
+== Related Compounds ==
+GBR-13119 is structurally related to other piperazine derivatives, such as [[GBR-12909]] and [[GBR-12935]], which also act as dopamine reuptake inhibitors.
+== Related Pages ==
-==See also==
 * [[Dopamine reuptake inhibitor]]
-* [[Diphenylmethane]]
+* [[Dopamine transporter]]
-* [[GBR-12909]]
+* [[Piperazine]]
-* [[GBR-13069]]
+* [[Neurotransmitter]]
-==References==
-<references />
-[[Category:Psychoactive drugs]]
-[[Category:Research chemicals]]
 [[Category:Dopamine reuptake inhibitors]]
-[[Category:Diphenylmethanes]]
+[[Category:Piperazines]]
-{{Psychoactive drug-stub}}
-{{Chemistry-stub}}